Accessibility Statement

Diversity, Equity & Inclusion



Management Approach

At Lilly, we believe in the power of diversity, equity and inclusion (DEI) to fulfill our purpose of creating medicines that make life better for people around the world. At our core, we know that by leveraging the varied backgrounds of our approximately 39,000 employees – and by driving actionable and measurable strategies to improve DEI, including diversity within our clinical trials – we can better deliver scientific breakthroughs that meet the needs of a broad and diverse set of people.

Our long-standing values of integrity, excellence and respect for people foster an environment where team members are encouraged to speak up, share ideas and be fully engaged in our work, while bringing their authentic selves to work every day. To fulfill our purpose, we believe we must look at challenges from multiple viewpoints and understand the diverse experiences of the people who depend on our medicines.

When Lilly employees come to work each day, we bring different experiences, perspectives and traditions, and we are committed to welcoming, respecting and valuing those differences. Because people are our priority – and they power our purpose – we treat DEI like any other priority business objective. We set strategy, goals and a variety of metrics to drive progress on attracting, developing, promoting and retaining a diverse workforce. We continually look at metrics and our performance and adjust as necessary so that our business and employee base better reflect the world around us.

Over the past eight years, we have conducted in-depth employee research that has yielded important insights into employee-reported experiences. The research uncovered factors that employees say significantly influence their ability to contribute to their fullest potential. This Employee Journeys research (explained further below) has led to a multifaceted People Strategy and companywide changes to improve our culture for everyone. Through our People Strategy, we have developed a comprehensive DEI strategy that strives to make working at Lilly better for everyone and helps deliver on our employee value proposition, “Be part of a team that cares about you and our shared purpose to make life better.”

Our commitment to DEI extends beyond our employees and into our broader business, including patient safety, clinical trials, access to and development of our medicines, and improving the diversity of our suppliers and partners.


Leadership Commitment

The DEI commitment at Lilly includes, among other things, high-level oversight, purposeful corporate culture and ongoing data analyses to inform our approach. Our CEO and Executive Committee consistently set expectations for inclusive leadership and hold leaders accountable for building diverse and inclusive teams. All executive officers have DEI goals included in their annual performance and compensation reviews.

Our executive leadership continues to integrate DEI within our human resources talent management organization. Lilly’s executive vice president for human resources and diversity, a member of our Executive Committee, reports directly to our chair and CEO and is ultimately accountable for DEI at Lilly. Our chief DEI officer is a senior vice president reporting to the executive vice president for human resources and diversity and is also responsible for leading our talent management functions. This allows us to fully embed DEI into how we recruit, develop, promote and retain talent. Our global head of DEI is a vice president who reports to the chief DEI officer.

We began setting internal aspirational goals in 2017 as part of our commitment to bolster the representation of women in management globally and minority group members in U.S. management roles. We also track recruitment and retention of employees on our research career path and the upper levels of our professional career path. We monitor our progress against aspirational goals over time to inform our approach.

Senior leaders have long coached, mentored and sponsored employees in their development as current and future Lilly business leaders. In 2022, our CEO sponsored leadership development programs for key talent, including U.S. minority group member and LGBTQ+ employees. Members of our Executive Committee – direct reports to our CEO – sponsored similar programs. Sponsorship efforts nearly doubled to more than 550 one-to-one sponsorship relationships in 2022. Both formal and informal mentoring has increased to more than 5,800 pairings.


DEI Progress

Building a more inclusive culture requires sustained focus and action and the holistic integration of DEI into our entire business. Leaders at Lilly are expected to lead more inclusively by valuing differences, recognizing and overcoming bias and fostering a speak-up culture where all colleagues feel their ideas and contributions are welcome and valued. We gauge employee feedback through surveys and other mechanisms.

Our commitment to DEI is a core component of how we do business. Here are some examples of how this work is making a difference:

  • Lilly is seeking to earn Management Leadership for Tomorrow (MLT) Black and Hispanic Equity at Work certifications. These certifications are gold-standards that focus on rigorous action with accountability, and include implementing a comprehensive Black and Hispanic equity plan focused on making meaningful, measurable progress across the five core MLT Equity at Work pillars: representation, compensation, workplace culture, business practices, and contributions and investments. 

  • Lilly will continue to advance DEI practices by participating in key external surveys and trackers that evaluate Lilly's DEI efforts compared with other participating companies.

  • Additionally, we track our progress, including the highlights below.

  • Management-level progress: Between the end of 2017 and the end of 2022 the number of women in management roles globally increased from 41% to over 49%. Representation of MGMs in U.S. management positions also increased during this time, from 16% at the end of 2017 to just below 25% at the end of 2022.

  • As of May 15, 2023, five members, or approximately 33%, of Lilly’s 15-member Executive Committee are women, and three members are minority group members. Our 12-member board of directors range in age from 50 to 68 and include five women and five members who are minority group members.


DEI Programs and Activities

Employee Journeys

We believe that fostering DEI begins with understanding, and we have approached DEI with the same rigor as our other business-critical priorities. Over the past eight years, our Employee Journeys research has yielded important insights about the experiences of women, Black American, Latinx, Asian and LGBTQ+ employees at Lilly. In response to insights from this research, we developed an education and awareness program to help build cultural literacy and understanding about expectations for employees to feel psychologically safe. We are conducting Employee Journeys research for employees with disabilities, which will conclude in 2024.

Our Employee Journeys research has contributed to growing energy around DEI across Lilly, including a company-wide network of DEI champions, functional DEI initiatives and DEI teams across business areas. The research continues to inform several internal initiatives, including Make It Safe to Thrive training and our psychological safety efforts, which are discussed below.

We strive to continually improve our ability to further embed DEI into the business, and we use learnings from our efforts to further inform our people strategy.

We recognize that there is more work to do, but these initiatives are making an impact. In our 2022 employee Pulse surveys, we saw continued progress on key questions related to inclusion such as “I speak up during meetings without worrying about how it will impact my relationships or career” and "I feel comfortable sharing my personal passions, interests and activities with the people I work with.”



Diversity-Driven Talent Acquisition

We believe cultivating diverse talent starts with the recruitment and hiring process and continues through the learning and development and advancement of people with wide-ranging backgrounds and experiences.

Lilly has a history of fostering diverse representation in our hiring practices with a focus on continuous improvement. In 2018, we began establishing aspirational goals for recruiting to strive for greater representation of women and minority groups throughout our workforce.

Recruiting aspirational goals are important to our overall recruiting strategy and progress. At the end of 2022, women comprised 51% of our global workforce. Maintaining our gains toward gender balance remains a key priority and we continue to focus on people development and retention.

Each year, we assess our aspirational recruiting goals for potential adjustments.


Clinical Trial Diversity

Every time someone takes a medicine – even if it’s over the counter – they are benefitting from the results of a clinical trial, a scientific study where researchers apply rigorous testing to ensure that medicine’s safety and effectiveness.

Many factors impact how someone will respond to a treatment, including their genetic background, ethnicity, gender and lifestyle. Because illness, including cancer, doesn’t discriminate, diverse participants in clinical trials are critical to developing safe and effective medicines for everyone.

Unfortunately, minority populations have been historically underrepresented in clinical trials. Although minorities make up nearly 40% of the U.S. population, they constitute less than 20% of participants in the key clinical trials that lead to the approval of new medicines, according to a 2015 study.

Lilly has established clear, measurable goals to increase diversity in our trials to better understand how the medicines we develop work for the patients who will be taking them.

These goals include:

  • Working to enroll trial participants who match the composition of the patient population that might use the trial’s medicine

  • Designing clinical trials to include diverse populations

  • Intentionally selecting a diverse range of clinical investigators in underrepresented patient geographies

  • Increasing diverse representation through education, partnerships and collaboration.


Racial Justice Commitment

Lilly aims to create a workplace, community and broader society where people from historically marginalized communities can move beyond systemic barriers and thrive. Bringing our purpose to life, driving change and addressing inequities has always been a part of our fabric. After the murder of George Floyd, we felt compelled to use our influence to do even more.

In 2020, Lilly and the Lilly Foundation launched the Racial Justice Commitment to help decrease the burden of racial injustice and its effects on communities of color. As part of this effort, Lilly pledged 25,000 volunteer hours and the Lilly Foundation committed $25 million over five years. The Racial Justice Commitment aims to drive change across five areas:internal people development, health equity, social impact, diversity partners and family sustaining jobs.


DEI Data

See our 2022 EEO-1 data.

2022 Data

Board Diversity

As of May 15, 2023, the company’s board composition includes five women and five minority group members on our 12-person board of directors.

U.S Workforce Ethnic Diversity

2018
2019
2020
2021
2022
Minority Group Member (MGM) Employees*
2018:
23%
2019:
27%
2020:
27%
2021:
28%
2022:
30%
Asians
2018:
9%
2019:
10%
2020:
10%
2021:
11%
2022:
11%
Black/African Americans
2018:
8%
2019:
10%
2020:
10%
2021:
9%
2022:
10%
Latinx
2018:
4%
2019:
5%
2020:
5%
2021:
5%
2022:
6%
Other
2018:
2%
2019:
2%
2020:
2%
2021:
3%
2022:
3%

*Numbers may not add due to rounding.

Minority Group Members in Management Positions (U.S.)

2018
2019
2020
2021
2022
Minority Group Members in Management Positions (U.S.)
2018:
19%
2019:
22%
2020:
22%
2021:
24%
2022:
24%

Gender Diversity at Lilly

2018
2019
2020
2021
2022
Women on Board
2018:
36%
2019:
31%
2020:
31%
2021:
31%
2022:
38%
Women on EC Team
2018:
43%
2019:
43%
2020:
43%
2021:
33%
2022:
33%
Women in Management (all M levels)
2018:
42%
2019:
45%
2020:
46%
2021:
48%
2022:
49%
Women in Global Workforce
2018:
48%
2019:
50%
2020:
50%
2021:
51%
2022:
51%
Women in U.S. Workforce
2018:
49%
2019:
50%
2020:
50%
2021:
50%
2022:
50%

See important information about our ESG report.